- Home
- Healthcare professionals
- ACE Technology Guidances
- Drug Guidance
- Denosumab for the prevention of skeletal-related events in adults with bone metastases from solid tumours
Drug guidance
Denosumab for the prevention of skeletal-related events in adults with bone metastases from solid tumours
Condition
Cancer
Musculoskeletal
3 May 2017
Published on 03 May 2017
Last Updated on 03 May 2017
Denosumab for the prevention of skeletal-related events in adults with bone metastases from solid tumours Guidance is outdated and has been withdrawn on 31 August 2022.
Denosumab for Bone Metastases (Withdrawn 31 Aug 2022) [PDF, 257 KB]